Abeona Therapeutics has reported its Q3 2025 financial results and provided corporate updates, including a shift in patient treatment timelines for ZEVASKYN®. While the delay is a negative factor, the company notes strong patient demand and an expanding treatment site network. Investors should weigh the delayed timeline against the underlying demand and growth potential. Careful monitoring of regulatory progress and commercialization efforts is advised.